ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Majority of Takeda investors want execs to return pay if deals flop

Measure failed to pass but shows shareholder concern over Shire acquisition

Takeda Pharmaceutical CEO Christophe Weber ranks among Japan's highest-paid executives.

TOKYO -- A provision to let Takeda Pharmaceutical claw back executive pay after a major loss or false accounting drew majority support from shareholders even while failing to pass, in a sign of the scrutiny Japan's top drugmaker faces over its roughly $60 billion purchase of Irish peer Shire.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more